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Abstract
Multiple system atrophy (MSA) is a rare neurodegenerative disease with a fatal out-
come. Nowadays, only symptomatic treatment is available for MSA patients. The
hallmarks of the disease are glial cytoplasmic inclusions (GCIs), proteinaceous aggre-
gates mainly composed of alpha-synuclein, which accumulate in oligodendrocytes.
However, despite the extensive research efforts, little is known about the pathogen-
esis of MSA. Early myelin dysfunction and alpha-synuclein deposition are thought to
play a major role, but the origin of the aggregates and the causes of misfolding are
obscure. One of the reasons for this is the lack of a reliable model of the disease.
Recently, the development of induced pluripotent stem cell (iPSC) technology
opened up the possibility of elucidating disease mechanisms in neurodegenerative
diseases including MSA. Patient specific iPSC can be differentiated in glia and neu-
rons, the cells involved in MSA, providing a useful human disease model. Here, we
firstly review the progress made in MSA modelling with primary cell cultures. Subse-
quently, we focus on the first iPSC-based model of MSA, which showed that alpha-
synuclein is expressed in oligodendrocyte progenitors, whereas its production
decreases in mature oligodendrocytes. We then highlight the opportunities offered
by iPSC in studying disease mechanisms and providing innovative models for testing
therapeutic strategies, and we discuss the challenges connected with this technique.
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1 | INTRODUCTION
Multiple-system atrophy, also known as MSA, is an adult onset
severe neurodegenerative disease characterized by glial cytoplas-
mic inclusions (GCIs) and progressive cellular death in selected
areas of central nervous system (CNS), more specifically the stria-
tonigral, olivopontocerebellar and central autonomic pathways. The
clinical presentation mirrors these alterations and comprises parkin-
sonism, cerebellar ataxia, pyramidal features and autonomic symp-
toms in various degrees.1 Two main clinical subtypes can
be identified and characterized by either a prevalence of parkinso-
nian symptoms (MSA-P) or a prevalence of cerebellar ataxia
(MSA-C).2
The estimated incidence ranges from 0.1 to 2.4 cases per
100 000 person-years, the mean value being 0.6-0.7/100 000.1,3
Prevalence has been reported to span between 1.9 and 4.9 per
100 000, according to different population studies.4,5 MSA-P
accounts for approximately two-thirds of the cases in European
countries, with regional differences,2,6,7 whereas MSA-C is far more
common in Japan.8
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Symptom onset occurs usually in the sixth decade, and the med-
ian survival from that time is estimated to be 9.8 years.9,10
In the majority of cases, MSA appears sporadically in the popula-
tion. However, some cases have been reported of Japanese, German
and American families showing a genetic transmission of the dis-
ease.11-16 Despite these findings, no disease-causing mutation could
be identified in these studies.
COQ2 is a gene that encodes the enzyme parahydroxybenzoate-
polyprenyl transferase, which catalyses one of the final reactions in
the biosynthesis of coenzyme Q10 (ubiquinone). Intriguingly, whole
genome sequencing of a Japanese family and large case-control ser-
ies revealed that COQ2 variants may be associated with an
increased risk of MSA in East Asia.17,18
However, other groups failed to report the same correlation
between MSA and COQ2 variants in western countries.19-21 These
findings notwithstanding, the role of COQ2 in the pathogenesis of
MSA remains unclear.
In addition to that, Gaucher disease-causing mutations of GBA
(glucocerebrosidase) gene were recently sequenced in 969 MSA
patients and in 1509 control subjects, demonstrating an association
between many GBA variant and MSA, as it happens in Parkinson’s
disease (PD).22
Finally, genomewide association studies (GWAS) have pointed
out possible correlation between alpha-synuclein encoding gene
(SNCA) polymorphisms and MSA.23,24 However, the largest MSA
GWAS did not find any relevant association.25 Additional studies
with more samples may shed new light on potentially significant
associations in future.
At a histopathological level, the main features of MSA are selec-
tive neuronal loss and axonal degeneration, alpha-synuclein
immunoreactive inclusions and gliosis. The pathologic hallmark of
MSA is insoluble GCIs, whose main proteinaceous component is
alpha-synuclein.26 Thus, the presence of GCIs characterizes MSA as
a “synucleinopathy,” together with PD and Lewy Body Dementia
(LBD). In contrast to inclusions in PD and LBD, however, GCIs pre-
dominantly accumulate in oligodendrocytes.27 Other relevant pro-
teins that can be found in aggregates are p25alpha/TPPP, LRRK2
and tau protein.28,29
GCIs are diffusely distributed in specific anatomical regions of
the CNS. More specifically, the pyramidal, striatonigral, corticocere-
bellar and preganglionic autonomic systems are affected in a prefer-
ential manner.30 GCIs are also widely present in the motor cortex,
despite mild levels of cellular degeneration.31
Nonetheless, glial alterations in the white matter are not limited
to oligodendrocytes, but involve also astrocytes and microglia. In
fact, the extent of reactive astrocytosis and activated microglia paral-
lels the degree and anatomical distribution of GCIs and neurodegen-
eration.32,33
Neuronal cytoplasmic inclusions (NCIs) and neuronal nuclear
inclusions (NNIs) can also be found in MSA, although less frequently
than GCIs.34 They are mainly found in cortical, subcortical, cerebellar
and brainstem nuclei, being especially prevalent in the pons and infe-
rior olivar nucleus.35
2 | THE PATHOGENESIS OF MULTIPLE
SYSTEM ATROPHY
To this day, the pathogenic mechanisms that lead to the develop-
ment of MSA are yet to be unravelled. Nevertheless, there is com-
pelling evidence that MSA is a primary oligodendrogliopathy, which
encompasses alpha-synuclein misfolding and aggregation, early mye-
lin dysfunction and axonal disease (Figure 1).36,37
Early myelin dysfunction is suggested by the finding that p25al-
pha (TPPP), usually found in myelin sheaths, relocates in the oligo-
dendrocyte soma in the first stages of the disease.38 Moreover, the
co-localization of p25alpha and MBP is noticeably decreased in MSA
brains, and total MBP content is reduced. The presence of p25alpha
in the body of the cell could then enhance the aggregation of alpha-
synuclein.39
The interaction between p25alpha and alpha-synuclein may
result in the formation of GCIs, which in turn interferes with oligo-
dendrocyte survival and neuronal support. Alpha-synuclein is thought
to play a major pathogenic role in the disease, although it is unclear
whether it is normally expressed in oligodendrocytes. Analysis of
postmortem healthy controls’ brains yielded contrasting results:
in situ hybridization techniques failed to detect alpha-synuclein
mRNA expression in glial cells,40,41 whereas a recent study identified
SNCA mRNA in oligodendrocytes using qPCR.42 Djelloul and col-
leagues sought evidence of the expression of alpha-synuclein in
oligodendrocyte lineages derived from mouse embryonic stem cells
(ESC) and human-induced pluripotent stem cells (iPSCs) and in oligo-
dendrocytes from mice postnatal forebrains. They found that alpha-
synuclein was expressed in oligodendrocytes progenitors, but its
levels decreased during maturation and were absent in the final
stages of differentiation.43
The origin of GCIs’ alpha-synuclein in MSA therefore is not clear.
One hypothesis is that it results from endogenous overexpression in
oligodendrocytes, notwithstanding that many studies contradict this
view. The in situ hybridization studies previously described did not
retrieve SNCA mRNA in MSA patients’ white matter.40,41 Analysis
by qPCR revealed the presence of alpha-synuclein transcripts but
the difference with PD patients and healthy controls was not statis-
tically significant.42 Furthermore, in vitro culturing of MSA-derived
iPSCs showed that, as in control and PD-derived lines, alpha-synu-
clein was expressed in the first stages of oligodendrocytes’ develop-
ment but not in the premyelinating phase.43 On the contrary,
upregulation of synuclein expression has been demonstrated to
impair the correct maturation of the oligodendrocyte.44
Another theory claims that alpha-synuclein might be produced in
neurons and then taken up by oligodendrocytes. Several studies
advocate this hypothesis, showing that oligodendrocytes are capable
to absorb neuronal secreted or exogenously added alpha-synuclein
both in vitro and in vivo.45,46 Under physiological conditions, alpha
synuclein is primarily produced by neuronal cells as an unfolded pro-
tein.47 Several studies showed that alpha-synuclein aggregates can
transmit from neuron to neuron,48 astroglial cells 49 and oligoden-
droglial cells,47 thus supporting the hypothesis of neuronal
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transmission. Oligodendrocytes are then able to take up alpha-synu-
clein via endocytotic mechanisms.50 Hansen and colleagues provided
evidence that alpha-synuclein may propagate from cell to cell and
exert a seeding effect on the endogenous protein, thereby contribut-
ing to the spread of the pathology.51 This discovery, along with a
recent study by Prusiner and colleagues, suggests that alpha-synu-
clein could disseminate in a prion-like fashion.52
The connection between alpha-synuclein accumulation and neu-
rodegeneration is still a matter of debate. According to some studies,
alpha-synuclein may have a role in activating intrinsic and extrinsic
apoptotic pathways within oligodendrocytes.53,54 Oligodendrocytes’
dysfunction then affects neuronal survival,55 for example through a
reduction in glial derived neurotrophic factor (GDNF).56 Moreover,
in vitro studies demonstrated that alpha-synuclein aggregates directly
induce neuronal dysfunction and apoptosis.48,57,58 Desplats and col-
leagues demonstrated the formation of inclusion bodies in neurons after
alpha-synuclein uptake, possibly through lysosomal dysfunction, and
apoptosis of involved neurons.48 Another study showed that exogenous
alpha-synuclein fibrils induce pathological alpha-synuclein accumulation,
neuron loss and diminished levels of synaptic proteins.58 Klucken and
colleagues found that inhibition of autophagy with bafilomicin A1
increased toxicity, measured as the release of adenylate kinase, in neu-
rons transfected with C-terminal modified a-synuclein.59 Impairment of
autophagic pathways has already been reported in nigral neurons of PD
patients’ brains 60 and evidence for a potential role of autophagy in
MSA pathogenesis is emerging from in vitro and in vivo studies.61,62
Furthermore, there is evidence that also inflammatory response,
whose main actors are microglia and astrocytes, plays an active role
in perpetuating and extending brain damage. Activated Iba-1-positive
microglia and GFAP-positive astrocytes are shown to colocalize with
GCIs.63 Moreover, treatment of primary astrocytes with alpha-synu-
clein triggered astrogliotic changes, whereas extracellular alpha-synu-
clein is phagocytosed by microglia inducing microgliosis and
production of reactive oxygen species (ROS).64 In particular, the Toll-
like receptors 2 and 4 are reported to interact with alpha-synuclein
and exhibit upregulation in MSA patients.65-67 Finally, it is suggested
that the release of cytotoxic products by activated glia may favour
alpha-synuclein misfolding and aggregation.68
In the light of the recent progress on the pathophysiological
mechanism, we now have a better understanding of how oligoden-
drocytes’ dysfunction and alpha-synuclein accumulation develop in
the human CNS. However, as symptoms in MSA patients appear to
be caused by neuronal degeneration, and not by demyelination in
oligodendrocytes, the molecular interactions between the degener-
ated oligodendrocytes have to be better elucidated.
Among the hypothesized mechanisms, oligodendrocytes’ dys-
function might cause neuronal death through the activation of neu-
roinflammatory mechanisms 63-67 and the loss of neurotrophic
support.56 Neuronal dysfunction because of a-synuclein inclu-
sions48,57,58 and autophagy impairment60-62 also act synergistically,
leading to neuronal death in the striatonigral, olivopontocerebellar
and central autonomic pathways.31 This secondary neurodegenera-
tion may explain the typical symptoms observed in MSA patients,
the lack of response to L-DOPA and the rapid progression of this
disease.
Demyelination plays an important role in advanced MSA,33 and
recent studies found that intracellular alpha-synuclein delays oligo-
dendrocytes maturation and myelination by downregulating myelin-
gene regulatory factor and myelin basic protein (MBP).44,69 Myelin
dysregulation is often followed by axonal degeneration,36 as demon-
strated by transgenic animal models.70,71
Several other mechanisms have been examined as potentially
pathogenic, such as proteasome system inhibition.72 A recent field
of investigation is focusing on exosomes, small extracellular vesi-
cles which are involved in the reciprocal communication between
oligodendrocytes and neurons, in neural trophic support and in
the regulation of microglial response. Exosomes appear able to
catalyse and accelerate the nucleation of alpha-synuclein. Exo-
somes are also suspected of playing a role in the prion-like spread
of proteins, such as alpha-synuclein, in neurodegenerative dis-
eases.73-75
In conclusion, many pathways, from gene expression to protein
transport and inflammatory response, appear to be involved and to
interact over the course of the disease. However, further investiga-
tions are needed to establish their precise role and weight in the
pathogenesis of MSA.
F IGURE 1 Hypothetical features of multiple system atrophy pathophysiology. Early in the course of the disease, p25alpha relocalizes into
the oligodendroglial soma. Subsequently, altered expression or uptake of alpha-synuclein in oligodendrocytes and interaction with p25alpha
causes the formation of glial cytoplasmic inclusions, which eventually determine oligodendroglial dysfunction and loss of neurotrophic support.
Misfolded alpha-synuclein can also be taken up by neurons, with the formation of neuronal cytoplasmic and nuclear inclusions. Defective
autophagic clearance mechanisms promote the accumulation of intracellular alpha-synuclein at an increased rate. Together with microglial
activation, these factors ultimately lead to neurodegeneration and neuronal death
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3 | INDUCED PLURIPOTENT STEM CELLS
IN NEURODEGENERATIVE DISEASES
In 2006, Takahashi and Yamanaka for the first time successfully
reprogrammed somatic cells, mouse fibroblasts at the beginning, into
embryonic like cells, the so-called iPSCs.76 The induction of pluripo-
tency in vitro can be achieved by overexpression of defined cocktail
of pluripotency-associated genes, or reprogramming factors, namely
Oct3/4, Sox2, Klf4 and c-Myc (OSKM), that are transduced in
somatic cells, usually fibroblasts, with a retroviral or lentiviral sys-
tem.77,78 This procedure allows to obtain cells similar to ESCs in
morphology, proliferation, surface antigens, gene expression, epige-
netic status and telomerase activity.
The mechanisms by which reprogramming factors exert their
action have not been completely elucidated. Oct3/4 and Sox2
upregulate stemness genes and suppress differentiation-associated
genes, acting synergistically.79 The role of Klf4 and c-Myc is less
clear, but it has been proposed that Klf4 favours epithelial transition
by binding to specific genes, while c-Myc seems to be involved in
the regulation of cellular proliferation, metabolism, and biosynthetic
pathways.80,81
The advantages of iPSCs over ESCs are numerous and relevant.
Firstly, while the use of ESCs is limited by ethical concerns because
of their embryonal origin, iPSCs are produced from adult cells and
thus they overcome this issue. Secondly, they retain the same genetic
makeup as the original source. Therefore, they allow the production
of patient-specific disease models and provide hope for the develop-
ment of therapies based on autologous iPSCs transplantations.
The challenges of this technique are the relative low efficiency
of the protocol, the risk of mutations following the genomic integra-
tion of transcription factors, the potential tumour risk if used as cell
source for transplantation, and the possibility of incomplete repro-
gramming.
Remarkably, the discovery of iPSCs has paved the way for direct
pharmacological reprogramming, a technique that was pioneered in
2016 by Zhang et al82 Further studies are needed to perfect this
method. However, there is a hope that the absence of genetic
manipulation could reduce the risk for genomic alterations.
iPSCs have already provided successful and patient-specific
models of different neurodegenerative diseases. Thanks to their
pluripotent phenotype, iPSCs can be differentiated in the various
cellular lines that are preferentially affected in the different diseases.
Neuronal and glial models of PD,83-86 Huntington’s disease,87-89
amyotrophic lateral sclerosis90-92 and Alzheimer’s disease93-95 have
already been realized.
4 | MODELLING MULTIPLE SYSTEM
ATROPHY IN VITRO: PRIMARY CELL
CULTURE AND LINES
One factor that makes MSA such a puzzling disease is the difficulty
to obtain reliable disease models. This is mainly because of its
complex neuropathologic features and to the lack of a recognized
genetic background. Moreover, different cell lineages are involved.
Despite the fact that aggregates are located mainly in oligodendro-
cytes, it is not clear whether alpha-synuclein originates from neurons
or glial cells. Both pharmacological (by stereotaxic injection of toxins)
and transgenic mouse models have been developed in the
past.70,71,96-104 However, those models were not able to precisely
recapitulate biological and clinical features of the disease. Moreover,
drugs that work in animals may not yield the same results in human
trials. Thus, there is a strong need for a precise and human-derived
in vitro model of MSA.
4.1 | Primary cell models
At first, in vitro studies were based on primary oligodendrocytic lin-
eages, such as OLN-93,105 derived from transformed rat oligodendro-
cytes or primary glial lineages, such as CG4,61,69 from rat brain and
U737,106 obtained from human glioblastoma-astrocytoma specimens.
Clonal cell lines were genetically modified so to overexpress alpha-
synuclein, as primary human and rat oligodendrocytes do not express
significant levels of alpha-synuclein (Table 1). In an early study, Ste-
fanova and colleagues transfected glial cultures with vectors pDSred-
N1 or pEGFP-N1 yielding plasmids encoding human wild-type and C-
terminally truncated form of alpha-synuclein. They found that the
overexpression of human alpha-synuclein produced widespread fibril-
lar a-synuclein aggregates and cellular damage, and that C-terminally
truncated form is much more prone to form aggregates than the full-
length alpha-synuclein. Unsurprisingly, they also observed that overex-
pression of alpha-synuclein enhanced cell death rates and increased
cell susceptibility to oxidative stress. Notably, these changes took
place both in astrocytes and in oligodendrocytes.106
Subsequently, Kragh and colleagues obtained a successful model
of glial degeneration by co-expressing human alpha-synuclein and
p25alpha in a rat oligodendroglial cell line, using the vector pET-
11d.106 As explained above, p25alpha appears to be implicated in
early myelin dysfunction in MSA and to induce alpha-synuclein
aggregation.39 In their study, they observed that coexpression of
alpha-synuclein and p25alpha caused a retraction of microtubules
from the cellular processes to the perinuclear region after the trans-
fection. This phase was followed by a lasting induction of apoptotic
markers with microscopically detectable caspase-3 activation and
nuclear chromatin condensation. Microtubules rearrangement was
dependent on coexpression of alpha-synuclein and p25alpha, as cells
tolerated alpha-synuclein expression and reacted only marginally to
the expression of p25alpha. Moreover, it was observed that phos-
phorylation of alpha-synuclein at Ser-129 is critical for its toxic
effect, as the expression of phosphorylation-deficient S129A mutant
resulted in absent microtubules retraction. This is an important find-
ing as Ser-129 phosphorylation hallmarks alpha-synuclein pathology
in tissues107 and was shown to mediate alpha-synuclein inclusion
formation in neurons.108
May and colleagues also developed a cellular model of MSA by
overexpressing human wild-type alpha-synuclein in a rodent
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oligodendroglial cell line, GC4.69 The expression of alpha-synuclein
was shown to impair oligodendrocyte progenitor cells (OPCs) matu-
ration, as human alpha-synuclein-expressing oligodendrocytes
demonstrated abnormal branching, a lower number of MBP positive
cells and a reduced intracellular MBP content at the final stages of
differentiation compared to controls. These results suggest that
accumulation of alpha-synuclein in OPCs may result in downregula-
tion of myelin-associated genes.
The group also found out that OPC content is increased in the
striatum of MSA-P patients and that mice overexpressing human
wild-type alpha-synuclein also display an increased number of striatal
OPCs. Thus, they hypothesized that alpha-synuclein may impair adult
oligodendrogenesis, preventing OPCs from remyelination and con-
tributing to MSA pathogenesis. Furthermore, the group found that
BDNF mRNA is significantly reduced in the striatum of MBP trans-
genic mice, and that the supplementation of BDNF in vitro to trans-
fected oligodendroglial cells partially rescues early OPCs’ maturation,
but lacks the potential to induce myelination.
Recently, Valera and colleagues generated a rodent oligoden-
droglial cell line, CG4, co-infected with Lentivirus expressing human
alpha-synuclein or control and microRNA-101 (miR-101a-3p) or con-
trol vector.61 The aim of the study was to investigate the potential
pathogenic role of microRNA-101 dysregulation in in vivo and
in vitro models of MSA. Dysregulation of autophagy appears to be
implicated in the pathogenesis and pathology of synucle-
inopathies,60,62 and alterations in microRNA-101 have been strongly
associated with autophagy impairments in human cancer mod-
els.109,110 They found that the coinfection of cells with alpha-synu-
clein and miR-101 led to autophagy inhibition (measured as a
decrease in autophagy proteins Beclin 1 and LC3 levels and an
increase in p62 protein levels) in CG4 cells compared to controls. To
confirm these results, CG4 were then infected with a lentiviral con-
struct expressing an antisense sequence against miR-101, which
resulted in a decrease in miR-101. Co-infection with alpha-synuclein
and antimiR-101 induced an increase in the LC3 signal, and a signifi-
cant decrease in the intracellular accumulation of alpha-synuclein,
suggesting that the repression of miR-101 may effectively promote
synuclein clearance in cellular models. The group also observed an
increase in miR-101 levels and a decrease in autophagy-associated
proteins in the striatum of MBP-alpha-synuclein transgenic mice.
Interestingly, autophagy-associated proteins co-localized with alpha-
synuclein and the oligodendroglial marker Olig2. Stereotaxic injection
of Lentivirus expressing anti-miR-101 resulted in an increase in the
aforementioned autophagic proteins levels.
4.2 | Achievements and limitations of primary cell
models
These studies played a fundamental role in defining some key events
in MSA pathogenesis. An important result that was observed is that
overexpression of a-synuclein in a human and rat primary mixed glial
culture is sufficient to produce widespread fibrillar a-synuclein
aggregates and to trigger cellular stress and degeneration.106 In addi-
tion to that, it was demonstrated that the accumulation of alpha-
synuclein in OPCs may downregulate myelin-associated genes and
impair adult oligodendrogenesis.69 Moreover, it was noted that the
co-expression of alpha-synuclein and p25alpha in OLN-93 cells gen-
erated a successful model of MSA-like degeneration, with alpha-
TABLE 1 In vitro models of multiple system atrophy
Authors Starting cells Main findings Reference
Stefanova et al (2005) U373 astrocytoma cell line and primary mixed rat
glial culture overexpressing human WT a-syn(1-
140) or C- terminally truncated a-syn (1-111)
under the CMV promotor.
Presence of widespread fibrillar a-syn aggregates, more
numerous in cells expressing the C-terminally truncated
form; increased cell death rates; increased susceptibility
to treatment with TNFa.
106
Kragh et al (2009) Oligodendroglial cell line (OLN-93) derived from
primary Wistar rat brain glial cultures expressing
human WT a-syn or S129A or S129D mutant a-
syn with human WT p25a.
Coexpression of a-syn and p25a causes microtubule
relocalization to the perinuclear region; p25a-mediated
microtubule retraction requires low levels of a-syn; a-
syn-dependent microtubule retraction induces apoptotic
markers with activation of caspase-3 and nuclear
chromatin condensation.
105
May et al (2014) Primary rodent oligodendroglial cell line (CG4)
expressing human WT a-syn under the CMV
promoter.
Intracellular a-syn impairs OPC maturation in vitro; BDNF
partially rescues OPC maturation.
69
Valera et al (2017) Primary rodent oligodendroglial cell line (CG4) co-
infected with Lentivirus expressing human a-syn
or LV control and microRNA-101 (miR-101a-3p)
or control vector.
Autophagy inhibition in CG4 cells compared to controls;
Lentiviral delivery of an antimiR-101 construct reduces
a-syn-induced autophagy deficits.
61
Djelloul et al (2015) iPSCs obtained from donors’ skin fibroblasts,
differentiated into oligodendrocytes.
O4+, OLIG2+, PDGFRA+ oligodendrocyte progenitors
express Snca and a-syn; their expression decreases in
MBP+, CNPASE+ premyelinating oligodendrocytes,
without significant differences among control and
patient lines.
43
Abbreviations: a-syn, alpha-synuclein; BDNF, brain-derived neurotrophic factor; OPC, oligodendrocyte progenitor cell; WT, wild type.
ABATI ET AL. | 5
synuclein aggregation and microtubule retraction in association with
activation of the apoptotic protein caspase 3.105 It was also demon-
strated that microRNA-101 overexpression induces autophagy
impairment in alpha-synuclein expressing cells and that its antago-
nization promotes synuclein clearance, thus paving the way for pos-
sible future therapeutic actions.61
However, studies based on primary cell cultures bear some limi-
tations. Despite these models were able to replicate some pathologi-
cal features of the disease, there is no evidence that alpha-synuclein
in MSA derives from endogenous overexpression in oligodendro-
cytes, and post-mortem analyses of MSA patients’ white matter by
in situ hybridization and qPCR failed to retrieve a significant differ-
ence in the presence of SNCA mRNA compared to healthy con-
trols.40-42 Moreover, while point mutations, duplications and
triplications of SNCA locus are associated with both sporadic and
familial variants of PD,111-113 no association was found between
these mutations and MSA. GWASs pointed out a possible correlation
between SNCA polymorphisms and MSA but subsequent studies
yielded contrasting results.23-25 Thus, the validity of oligodendrocytic
alpha-synuclein upregulation as a model for the disease pathogenesis
is limited.
In addition to that, common permanent oligodendrocyte cell lines
have undergone various genetic modifications to drive immortal cell
growth. For this reason, it may be difficult to determine whether
results observed in tissue culture are artefacts or disease-specific
alterations.
5 | MODELLING MULTIPLE SYSTEM
ATROPHY IN VITRO BASED ON IPSC
Recently, iPSC obtained from patients have elicited new hopes in
this field. Neurons and oligodendrocytes derived from MSA patients’
iPSCs could yield new insights into the pathogenic process.
5.1 | Differentiating iPSCs into oligodendrocytes
In this regard, one of the main challenges is represented by the nature
of the cells targeted by MSA. In fact, oligodendrocytes’ maturation
in vitro is longer and more complex than neuronal one.114,115 This is
because neural stem cells (NSCs), in the absence of exogenous mor-
phogens, commit to a dorsal telencephalic fate, more specifically to
glutamatergic lineage.116 NSCs can switch to oligodendroglial progeni-
tors by co-expressing Olig2 with Nkx2.2 and Sox10. Thus, in most
protocols, pluripotent stem cells are treated with SHH for the first 10
to 12 days in order to induce expression of Olig2. SHH can be
replaced with purmorphamine114 or SAG.115 Dual inhibition of SMAD
signalling with the combined use of the molecules SB431542 and
LDN193189 has been shown to accelerate the production of Pax6+
NSCs and to upregulate Olig2, thereby generating the highest yield of
Olig2+ progenitors.115,117 This first part of differentiation, which
includes the induction of neuroepithelium and then of Olig2-expres-
sing progenitors, generally takes place in adherent cultures.
Subsequently, continuous stimulation of SHH pathway is neces-
sary to induce the formation of Olig2+, Nkx2.2+ pre-OPCs. In con-
trast to the previous stage, transition from neuroepithelium to pre-
OPCs is best carried out as floating aggregates.115
Differentiation to Sox10+, PDGFR+ OPCs is a long process that
may take up to 10 weeks. In order to boost the transition, most pro-
tocols introduce between the third and the fifth week a cocktail of
factors known to drive oligodendrocyte differentiation or to promote
oligodendrocyte survival, namely platelet-derived growth factor
(PDGF), neurotrophin 3 (NT3), triiodo-L-thyronine (T3), insulin-like
growth factor 1 (IGF-1) and hepatocyte growth factor (HGF).114,115,117
Last steps of differentiation require the withdrawal of mitogenic
factors and result in the production of O4+ immature oligodendro-
cyte and finally in the appearance of MBP+ ramified, mature oligo-
dendrocytes.115
5.2 | Generation of an iPSC-based MSA model
MSA oligodendrocytes have been successfully generated by Djelloul
and colleagues (Table 1).43 In their work, they generated iPSCs from
skin fibroblasts of one MSA-C patient, one MSA-P patient, one
familial PD patient and one healthy control, performing karyotype
analysis in order to rule out possible chromosomal abnormalities.
Subsequently, they differentiated them into functional oligodendro-
cytes using dual inhibition of SMAD signalling by small molecules
LDN and SB and PDGF-AA/IGF1/NT3/T3/HGF-mediated terminal
differentiation. Finally, they evaluated alpha-synuclein expression by
immunocytochemistry (ICC) and measured SNCA gene transcripts by
real-time PCR in the diverse lines at different stages of maturation.
By day 60 in vitro, O4+, OLIG2+, PDGFRA+ oligodendrocyte pro-
genitors showed the presence of SNCA transcripts and the expres-
sion of alpha-synuclein, that was present also in neurons, while it
was absent in astrocytes. Notably, the presence of alpha-synuclein in
oligodendrocytes decreased during maturation in all cell lines, includ-
ing the diseased ones. Furthermore, they observed the relocation of
alpha-synuclein during oligodendrocyte differentiation from the pro-
cesses to the perinuclear space. Interestingly, disease lines gave rise
to an accelerated high yield of O4+ progenitors by day 70 in vitro.
To confirm these results, postnatal mouse forebrain primary cul-
tures and mESC-derived oligodendrocytic cultures were analysed for
the presence of alpha-synuclein and SNCA gene transcripts. Interest-
ingly, in mouse brain primary cultures, alpha-synuclein showed speci-
fic localization in B-III-Tubulin+ neurons and in O4+
oligodendrocytes. Analysis by real-time PCR in both lines demon-
strated the presence of SNCA transcripts in O4+ oligodendrocytes.
A strong reduction in the expression of alpha-synuclein was then
observed in mature CNPASE- and MBP-expressing oligodendrocytes,
both in forebrain and in mESC-derived cultures.
5.3 | Relevance of the first iPSC-based MSA model
This study suggests that oligodendrocytes might be able to produce
alpha-synuclein in vivo, at least during the first stages of maturation.
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However, the implications of these findings have not been com-
pletely understood yet. No significant differences in the expression
of alpha-synuclein were observed between healthy and diseased cell
lines. This result might support the hypothesis that alpha-synuclein
found in MSA inclusions does not originate from oligodendrocytes,
but on the contrary it is produced in neurons and subsequently
taken up by oligodendrocytes. However, further research is needed
to confirm this finding in a greater number of MSA-derived iPSC
lines. Neuronal-oligodendroglial co-cultures might be used to investi-
gate possible mechanisms of synuclein uptake. Whether the acceler-
ated production of immature oligodendrocytes in diseased cell could
be ascribed to a greater oligodendrogenesis, probably triggered by
cell injury, remains to be determined.
5.4 | Promises and limitations of iPSC-based
models in MSA studies
Since their discovery, iPSCs have raised many hopes for the devel-
opment of disease-specific models that could replicate pathogenic
events in vitro. Although in its infancy, MSA-specific iPSC technol-
ogy could be the key to solving some of the enigmas surrounding
this disease. The advantages of this technique are that it is patient
derived, and it allows to study neural and oligodendroglial matura-
tion from their first stages. Therefore, it could be useful for elucidat-
ing mechanisms prior to alpha-synuclein misfolding and
accumulation, such as the origin of alpha-synuclein in GCIs and the
role of transcriptional upregulation of SNCA. Impairment of oligo-
dendroglial precursors’ maturation and myelination was shown to be
involved in MSA pathogenesis.33,44,69 Thus, studying the various
steps of oligodendrocytes generation and maturation through iPSC
technology might help clarifying early events in MSA pathogenesis.
Moreover, myelin lipids (sphingomyelin, sulfatide, and galactosylce-
ramide) were found to be decreased in the affected white matter of
MSA patients.118 These findings suggest that targeting lipid synthesis
pathway at different steps of maturation might reproduce some of
the neuropathologic features of MSA and possibly explain the extent
of the contribution of myelin proteins dysregulation in disease
pathogenesis.118 Another unresolved issue in MSA pathogenesis is
whether neurodegeneration is a primary event or a consequence of
oligodendroglial disfunction. Unravelling the pathways that lead to
cell death is essential to find potential therapeutic targets. For exam-
ple, recent in vitro studies highlighted the role of autophagy and
defective intracellular clearance in alpha-synuclein toxicity.59,61,62
Valera and colleagues targeted a specific regulator of autophagy,
microRNA-101, in order to create a model of MSA and to identify
potential therapeutic agents.61 iPSCs can be differentiated into many
cell types and thus it could be possible to study degenerative path-
ways both in affected neurons and in oligodendrocytes. Moreover,
patient-derived iPSCs could generate not only simple oligoden-
droglial or neuronal cultures, but also mixed oligodendroglial-neuro-
nal cultures, which could then be searched for differential expression
of alpha-synuclein, apoptotic markers and other relevant proteins.
Mixed oligodendroglial and neuronal cultures could also represent a
useful tool to study trophic interaction between neurons and oligo-
dendrocytes. A reduction in GDNF was observed in transgenic
mouse models of MSA, and it is believed to play a role in neurode-
generation.56 Co-cultures could expand our knowledge about the
role of GDNF and other trophic factors in the neuropathological
alterations found in MSA. Furthermore, both direct intercellular
transmission mechanisms47-49 and exosomes73-75 were shown to be
involved in alpha-synuclein propagation. These interactions could be
better analysed in co-cultures. Another exciting possibility is the cre-
ation of organoids, iPSC-based tridimensional cellular cultures, which
reproduce human brain tissues with their different cell types and
complex cellular interactions.119 Although these techniques have not
been used for studying MSA so far, significant advancements have
been made in other fields.
On the other hand, studying a disease such MSA with iPSCs
poses many challenges. The absence of a “smoking gun” gene defect
means it is extremely difficult to model MSA with stem cells. Like-
wise, the lack of a precise knowledge about the role of environmen-
tal influences in the pathogenesis challenges the validity of in vitro
results. Hence, many different diseased cell lines and controls would
be necessary to state that a finding is not an artefact, making
research of this kind long and expensive.
Having made these points, iPSCs still remain the best technique
to study MSA at a preclinical level so far. Both animal models and
primary cultures require some kind of manipulation to overexpress
alpha-synuclein, despite it is not known whether such a mechanism
is responsible or not for MSA pathogenesis. As genetic research
about MSA is making important progresses, it is possible that in a
near future we will be able to identify mutations or polymorphisms
associated with the disease.
6 | CONCLUSIONS AND FUTURE
PERSPECTIVES
Despite the many studies that have been conducted, MSA pathogen-
esis remains elusive. Surely, the paucity of reliable disease models
represents a significant obstacle for researchers. Different groups
attempted to reproduce the features of the disease by genetically
reprogramming primary glial lines.61,69,105,106 These models were
useful to investigate the effects of the overexpression of alpha-synu-
clein and p25alpha on oligodendrocytes’ maturation and survival. It
was observed that the excessive production of alpha-synuclein at an
oligodendroglial level causes the formation of fibrillary alpha-synu-
clein aggregates and favours cell death.106 In another study, the con-
comitant expression of p25alpha was shown to induce alpha-
synuclein aggregation and the subsequent activation of the apoptotic
cascade.105 Furthermore, it was seen that overexpression of alpha-
synuclein in OPCs impaired their normal maturation and myelination,
possibly through a downregulation of myelin-associated genes.69 In
addition to that, the presence of a dysregulation of autophagic path-
ways and its contribution to the intracellular deposition of alpha-
synuclein was analysed.61 However, these models have several flaws,
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as they are not based on patient-derived cultures and thus they do
not share the same genetic background as patients. Moreover, it is
not known whether alpha-synuclein is primarily overexpressed in
oligodendrocytes or if MSA neuropathological features originate
from the interaction between neurons and oligodendrocytes. There-
fore, models based on primary cell cultures are of limited use in drug
testing.
Conversely, the advent of iPSC technology opens up thrilling
possibilities for the study of neurodegenerative diseases such as
MSA. iPSC-based models are human relevant, and they retain the
same genetic inheritance as the patient. Thus, they raise hopes on
the possibility of testing drugs in a safe and reliable manner, and
developing treatments based on autologous stem cell transplanta-
tion. Furthermore, the use of stem cells allows researchers to
observe neurons and glial cells during their differentiation and matu-
ration, making it possible to identify early events that could trigger
late neurodegeneration. Djelloul and colleagues were the first to
generate oligodendrocytes from iPSCs of patients with MSA. Their
work shows that alpha-synuclein is produced in oligodendrocytes
progenitors and registers a significant decrease during maturation,
but no differences were observed between healthy and MSA cell
lines.43 However, it was noted that disease lines generated a higher
yield of O4+ progenitors at an accelerated rate. Although these
results suggest the hypothesis that GCIs’ alpha-synuclein might not
originate from oligodendrocytes, further models are needed to con-
firm these findings.
iPSC technology also poses a variety of challenges. The absence
of known genetic or environmental culprits makes it difficult to
determine whether MSA is one disease or many. As a consequence,
the validity and significance of in vitro results obtained from
patients’ iPSCs needs to be confirmed with a great number of obser-
vations.
In conclusion, although we are far from the understanding of dis-
ease mechanisms, future research may take advantage from the
uncountable opportunities offered by IPSCs. For example, co-cul-
tures of neurons and oligodendrocytes may shed light on the cellular
origin of alpha-synuclein. Furthermore, iPSC-based tridimensional
cellular cultures, or organoids, may provide an excellent insight into
MSA pathogenesis, as they reproduce complex cellular interaction in
a near-physiological environment.119 In addition to that, MSA-
derived iPSC cultures may allow scientists to focus on molecular
changes that occur in patients prior to neurodegeneration or symp-
toms onset. The identification of markers of subclinical disease may
be the first step towards early diagnosis and effective pharmacologi-
cal interventions.
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